Literature DB >> 11294826

The effects of amiodarone on the thyroid.

E Martino1, L Bartalena, F Bogazzi, L E Braverman.   

Abstract

Amiodarone is a benzofuranic-derivative iodine-rich drug widely used for the treatment of tachyarrhythmias and, to a lesser extent, of ischemic heart disease. It often causes changes in thyroid function tests (typically an increase in serum T(4) and rT(3), and a decrease in serum T(3), concentrations), mainly related to the inhibition of 5'-deiodinase activity, resulting in a decrease in the generation of T(3) from T(4) and a decrease in the clearance of rT(3). In 14-18% of amiodarone-treated patients, there is overt thyroid dysfunction, either amiodarone-induced thyrotoxicosis (AIT) or amiodarone-induced hypothyroidism (AIH). Both AIT and AIH may develop either in apparently normal thyroid glands or in glands with preexisting, clinically silent abnormalities. Preexisting Hashimoto's thyroiditis is a definite risk factor for the occurrence of AIH. The pathogenesis of iodine-induced AIH is related to a failure to escape from the acute Wolff-Chaikoff effect due to defects in thyroid hormonogenesis, and, in patients with positive thyroid autoantibody tests, to concomitant Hashimoto's thyroiditis. AIT is primarily related to excess iodine-induced thyroid hormone synthesis in an abnormal thyroid gland (type I AIT) or to amiodarone-related destructive thyroiditis (type II AIT), but mixed forms frequently exist. Treatment of AIH consists of L-T(4) replacement while continuing amiodarone therapy; alternatively, if feasible, amiodarone can be discontinued, especially in the absence of thyroid abnormalities, and the natural course toward euthyroidism can be accelerated by a short course of potassium perchlorate treatment. In type I AIT the main medical treatment consists of the simultaneous administration of thionamides and potassium perchlorate, while in type II AIT, glucocorticoids are the most useful therapeutic option. Mixed forms are best treated with a combination of thionamides, potassium perchlorate, and glucocorticoids. Radioiodine therapy is usually not feasible due to the low thyroidal radioiodine uptake, while thyroidectomy can be performed in cases resistant to medical therapy, with a slightly increased surgical risk.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11294826     DOI: 10.1210/edrv.22.2.0427

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  87 in total

1.  Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment.

Authors:  Matthew L Rosene; Gábor Wittmann; Rafael Arrojo e Drigo; Praful S Singru; Ronald M Lechan; Antonio C Bianco
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

2.  Thyroid hormone enhances the formation of synapses between cultured neurons of rat cerebral cortex.

Authors:  Ritsuko Hosoda; Kenji Nakayama; Midori Kato-Negishi; Masahiro Kawahara; Kazuyo Muramoto; Yoichiro Kuroda
Journal:  Cell Mol Neurobiol       Date:  2003-12       Impact factor: 5.046

3.  The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.

Authors:  L Tomisti; C Urbani; G Rossi; F Latrofa; C Sardella; L Manetti; I Lupi; C Marcocci; L Bartalena; O Curzio; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2016-01-13       Impact factor: 4.256

4.  Association between N-desethylamiodarone/amiodarone ratio and amiodarone-induced thyroid dysfunction.

Authors:  Mikie Yamato; Kyoichi Wada; Mai Fujimoto; Kouichi Hosomi; Tomohiro Hayashi; Akira Oita; Mitsutaka Takada
Journal:  Eur J Clin Pharmacol       Date:  2017-01-12       Impact factor: 2.953

Review 5.  [Therapy related alterations to the thyroid gland].

Authors:  S Y Sheu; S Levin; K W Schmid
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

6.  Long-term lithium treatment and thyroid antibodies: a controlled study.

Authors:  Christopher Baethge; Holger Blumentritt; Anne Berghöfer; Tom Bschor; Tasha Glenn; Mazda Adli; Peter Schlattmann; Michael Bauer; Reinhard Finke
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

7.  To add amiodarone or not: that is the question.

Authors:  Matthew Jason Zimmerman; Myron C Gerson
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

8.  [Hypothyroidism due to amiodarone: importance of monitoring].

Authors:  R Casañ Fernández; O Juan Vidal
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

9.  Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction.

Authors:  Mikie Yamato; Kyoichi Wada; Tomohiro Hayashi; Mai Fujimoto; Kouichi Hosomi; Akira Oita; Mitsutaka Takada
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

10.  Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis.

Authors:  F Bogazzi; E Martino; E Dell'Unto; S Brogioni; C Cosci; F Aghini-Lombardi; C Ceccarelli; A Pinchera; L Bartalena; L E Braverman
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.